Henan Taloph Pharmaceutical Stock Co. Ltd. Class A

Henan Taloph Pharmaceutical Stock Co. Ltd. Class A

SSSE:600222
6.15
CNY
-0.09
(-1.44%)
0.10EPS
85.72P/E
4.41BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A carries a market capitalization of 4.41B, placing it among publicly traded companies globally. Its enterprise value stands at 5.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.41B
Enterprise Value5.23B

Share Statistics

As of September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A has 559.36M shares outstanding.

Shares Outstanding559.36M

Valuation Ratios

As of September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 85.72. The price-to-sales ratio is 2.56, and the price-to-book ratio stands at 2.72.

PE Ratio85.72
PS Ratio2.56
PB Ratio2.72
P/TBV Ratio3.52

Enterprise Valuation

As of September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A trades at an EV/EBITDA multiple of 72.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 72.51 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.23B versus a market cap of 4.41B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.07
EV / EBITDA72.51
EV / EBIT72.51

Financial Position

As of September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A maintains a current ratio of 1.24, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.03, indicating elevated leverage, while an interest coverage ratio of 1.34 demonstrates limited ability to service its debt obligations.

Current Ratio1.24
Quick Ratio0.15
Debt / Equity61.03
Debt / EBITDA14.23
Interest Coverage1.34

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 817,459.62 in revenue per employee across its workforce of 2,084.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee817,459.62
Employee Count2,084.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A recorded 16.07M in income tax expense. That works out to an effective tax rate of 22.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 72.15M, leaving 50.91M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax16.07M
Effective Tax Rate22.28

Stock Price Statistics

CNY

As of the close on November 17, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A's stock has declined approximately 21.76% over the past 52 weeks. The 50-day moving average sits at 7.32, while the 200-day moving average is 7.36.

52-Week Price Change-21.76%
50-Day Moving Average7.32
200-Day Moving Average7.36

Income Statement

CNY

Over the twelve months ended September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A generated 1.70B in revenue and converted that into 50.91M in net income, yielding earnings per share of 0.10. EBITDA reached 72.09M, while operating income came in at 156.05M.

Revenue1.70B
Gross Profit464.41M
Operating Income156.05M
Pretax Income72.15M
Net Income50.91M
EBITDA72.09M
EBIT72.09M
Earnings Per Share (EPS)0.10

Balance Sheet

CNY

As of September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A holds 272.50M in cash and equivalents against 1.03B in total debt, resulting in a net debt position of 500.42M. Total book value stands at 1.62B, with working capital of 449.10M providing operational flexibility.

Cash & Cash Equivalents272.50M
Total Debt1.03B
Net Debt500.42M
Equity (Book Value)1.62B
Book Value Per Share2.90
Working Capital449.10M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-16.66M

Margins

Over the twelve months ended September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A posted a gross margin of 27.26, reflecting its pricing power and cost economics. The operating margin of 9.16 and net profit margin of 2.99 provide insight into operational efficiency.

Gross Margin27.26
Operating Margin9.16
Pretax Margin4.24
Profit Margin2.99
EBITDA Margin4.23

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A paid dividends of 0.11 per share. The dividend payout ratio of 101.14 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 5.51, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Henan Taloph Pharmaceutical Stock Co. Ltd. Class A shareholders.

Dividend Per Share0.11
Payout Ratio101.14
Shareholder Yield5.51

Stock Splits

Henan Taloph Pharmaceutical Stock Co. Ltd. Class A's most recent stock split took place on May 12, 2010 with a 10:13 split ratio.

Last Split Date5/12/2010
Split Ratio10:13

Scores

As of September 30, 2026, Henan Taloph Pharmaceutical Stock Co. Ltd. Class A has an Altman Z-Score of 2.23, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.23